Ganesh A, Rosentreter RE, Chen Y, Mehta R, McLeod GA, Wan MW, Krett JD, Mahjoub Y, Lee AS, Schwartz IS, Richer LP, Metz LM, Smith EE, and Hill MD
Background: Various neurologic manifestations have been reported in patients with COVID-19, mostly in retrospective studies of patients admitted to hospital, but there are few data on patients with mild COVID-19. We examined the frequency and persistence of neurologic/neuropsychiatric symptoms in patients with mild COVID-19 in a 1-year prospective cohort study, as well as assessment of use of health care services and patient-reported outcomes., Methods: Participants in the Alberta HOPE COVID-19 trial (hydroxychloroquine v. placebo for 5 d), managed as outpatients, were prospectively assessed 3 months and 1 year after their positive test result. They completed detailed neurologic/neuropsychiatric symptom questionnaires, the telephone version of the Montreal Cognitive Assessment (T-MoCA), the Kessler Psychological Distress Scale (K10) and the EuroQol EQ-5D-3L (measure of quality of life). Close informants completed the Mild Behavioural Impairment Checklist (MBI-C) and the Informant Questionnaire on Cognitive Decline in the Elderly. We also tracked use of health care services and neurologic investigations., Results: The cohort consisted of 198 participants (87 female [43.9%] median age 45 yr, interquartile range 37-54 yr). Of the 179 participants with symptom assessments, 139 (77.6%) reported at least 1 neurologic symptom, the most common being anosmia/dysgeusia (99 [55.3%]), myalgia (76 [42.5%]) and headache (75 [41.9%]). Forty patients (22.3%) reported persistent symptoms at 1 year, including confusion (20 [50.0%]), headache (21 [52.5%]), insomnia (16 [40.0%]) and depression (14 [35.0%]); 27/179 (15.1%) reported no improvement. Body mass index (BMI), a history of asthma and lack of full-time employment were associated with the presence and persistence of neurologic/neuropsychiatric symptoms; female sex was independently associated with both (presence: odds ratio [OR] adjusted for age, race, BMI, history of asthma and neuropsychiatric history 5.04, 95% confidence interval [CI] 1.58 to 16.10). Compared to participants without persistent symptoms, those with persistent symptoms had more hospital admissions and family physician visits, and worse MBI-C scores and less frequent independence for instrumental activities at 1 year (83.8% v. 97.8%, p = 0.005). Patients with any or persistent neurologic symptoms had worse psychologic distress (K10 score ≥ 20: adjusted OR 12.1, 95% CI 1.4 to 97.2) and quality of life (median EQ-5D-3L visual analogue scale rating 75 v. 90, p < 0.001); 42/84 (50.0%) had a T-MoCA score less than 18 at 3 months, as did 36 (42.9%) at 1 year. Participants who reported memory loss were more likely than those who did not report such symptoms to have informant-reported cognitive-behavioural decline (1-yr MBI-C score ≥ 6.5: adjusted OR 15.0, 95% CI 2.42 to 92.60)., Interpretation: Neurologic/neuropsychiatric symptoms were commonly reported in survivors of mild COVID-19, and they persisted in 1 in 5 patients 1 year later. Symptoms were associated with worse participant- and informant-reported outcomes. Trial registration: ClinicalTrials.gov, no. NCT04329611., Competing Interests: Competing interests: Aravind Ganesh reports membership on the editorial boards of Neurology, Stroke and Neurology Clinical Practice; consulting fees and honoraria from Atheneum, MD Analytics, Figure 1, MyMedicalPanel, Creative Research Designs, CTC Communications Corp, Alexion and Biogen; research support from Alberta Innovates, Campus Alberta Neuroscience, the Canadian Cardiovascular Society, the University of Calgary (Hotchkiss Brain Institute), the Sunnybrook Research Institute INOVAIT program and the Canadian Institutes of Health Research (CIHR), outside the submitted work; and stock/stock options from SnapDx and Let’s Get Proof. He has a patent application (US 17/317,771) for a system for prehospital patient monitoring/assessment and delivery of remote ischemic conditioning or other cuff-based therapies. Ryan Rosentreter reports the same patent application (US 17/317,771). Luanne Metz reports grant funding from the MS Society of Canada, outside the submitted work. Eric Smith reports grant funding from the CIHR, Brain Canada and the Weston Brain Institute, outside the submitted work; consulting fees from Bayer, Biogen and Javelin Technologies; royalties from UpToDate; and payment from the American Heart Association for work as associate editor of Stroke. Michael Hill is a director of the Canadian Neurological Sciences Federation and the Canadian Stroke Consortium. He reports consulting fees from BrainsGate; industry grant support to the University of Calgary from NoNO, Biogen, Medtronic and Boehringer-Ingelheim Canada; and public grant support to the University of Calgary from Alberta Innovates, CIHR, the Heart & Stroke Foundation of Canada, and the National Institute of Neurological Disorders and Stroke. He reports a patent to US Patent office (US 62/086,077) issued and licensed. He owns stock in PureWeb. No other competing interests were declared., (© 2023 CMA Impact Inc. or its licensors.)